Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137

Site search

Correspondence address
310 Mira Street, Stavropol, Russia, 355017

+7 865 2352511, +7 865 2353229.


Relationship of metabolic syndrome with adhesion molecules in non-alcoholic fatty liver disease

[Original research]
Pavel Koroy; Sergey Slyadnev; Alexandr Yagoda;

Relationship of adhesion molecules with features of metabolic syndrome was studied in 208 patients with nonalcoholic fatty liver disease (NAFLD). Maximal values of ICAM-1 and VCAM-1 in blood were observed in cases of abdominal obesity or disorders of lipid metabolism. Hyperinsulinemia or hyperglycemia were characterized by increased levels of VCAM-1 and PECAM-1 in patients with NAFLD. Combination of NAFLD with insulin resistance or with arterial hypertension was accompanied by raised levels of all adhesion molecules. Metabolic syndrome was associated with disbalance of intercellular mediators as elevation of concentration of ICAM-1, VCAM-1, and PECAM 1 with increase in quantity of criteria of metabolic syndrome. Levels of ICAM-1 more than 848 ng/ml, VCAM-1 above 2355 ng/ml, PECAM-1 more than 70 ng/ml have been connected with the increased chance of presence of metabolic syndrome in NAFLD.


1. Nolan P. B., Carrick-Ranson G., Stinear J. W., Reading S. A., Dalleck L. C. Prevalence of metabolic syndrome and metabolic syndrome components in young adults: a pooled analysis. Prev. Med. Rep. 2017;7:211-215. https://doi.org/10.1016/j.pmedr.2017.07.004
2. Rochlani Y., Pothineni N. V., Kovelamudi S., Mehta J. L. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther. Adv. Cardiovasc. Dis. 2017;11(8):215-225. https://doi.org/10.1177/1753944717711379
3. Koroy P. V., Slyadnev S. A., Kravchenko Yu. A., Yagoda A. V. Influence of metabolic syndrome on course of non-alcoholic fatty liver disease. Terapiya. – Therapy. 2019;5(3):37-42. (In Russ.). https://doi.org/10.18565/therapy.2019.3.37-42
4. Grander C., Grabherr F., Moschen A. R., Tilg H. Non-alcoholic fatty liver disease: cause or effect of metabolic syndrome. Visc. Med. 2016;32(5):329-334. https://doi.org/10.1159/000448940
5. Yang K. C., Hung H.-F., Lu C.-W., Chang H.-H., Lee L.-T., Huang K.-C. Association of non-alcoholic fatty liver disease with metabolic syndrome independently of central obesity and insulin resistance. Sci. Rep. 2016;6:27034. https://doi.org/10.1038/srep27034
6. Chatrath H., Vuppalanchi R., Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin. Liver. Dis. 2012;32(1):22-29. https://doi.org/10.1055/s-0032-1306423
7. Chalasani N., Younossi Z., Lavine J. E., Charlton M., Cusi K. [et al.]. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67(1):328-357. https://doi.org/10.1002/hep.29367
8. Stepanova M., Younossi Z. M. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin. Gastroenterol. Hepatol. 2012;10(6):646-650. https://doi.org/10.1016/j.cgh.2011.12.039
9. Bae Y.-J., Kim S.-H., Chung J.-H., Song S.-W., Kim K.-S. [et al.]. Evaluation of adiposity-related biomarkers as metabolic syndrome indicators. Clin. Nutr. Res. 2013;2(2):91-99. https://doi.org/10.7762/cnr.2013.2.2.91
10. Tadzic R., Mihalj M., Vcev A., Ennen J., Tadzic A., Drenjancevic I. The effects of arterial blood pressure reduction on endocan and soluble endothelial cell adhesion molecules (CAMs) and CAMs ligands expression in hypertensive patients on Ca-channel blocker therapy. Kidney Blood Press. Res. 2013;37(2-3):103-115. https://doi.org/10.1159/000350064
11. Koroy P. V., Yagoda A. V., Slyadnev S. A. Sostoyanie adgezivnoy funktsii endoteliya pri nealkogol’noy zhirovoy bolezhni pecheni. Vrach. – Doctor. 2017;5:19-22. (In Russ.).
12. Yagoda A. V., Koroy P. V., Slyadnev S. A. Positive correlation of the level of molecules of superselective immunoglobulins ICAM-1, VCAM-1 and PECAM-1 with the index of fibrosis in nonalcoholic fatty liver disease Eksperimental’naya i Klinicheskaya Gastroenterologiya. – Experimental and clinical gastroenterology. 2017;138(2):45-51. (In Russ.).
13. Takaki A.,. Kawai D., Yamamoto K. Мultiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). Int. J. Mol. Sci. 2013;14(10):20704-20728. https://doi.org/10.3390/ijms141020704
14. Ataya A. E., Esenb B., Akbasc H., Gokmen E. S., Pilten S. [et al.]. ICAM-1 level and ICAM-1 gene 1462A>G (K469E) polimorphism on microalbuminuria in nondiabetic, nonhypertensive and normolipidemic obese patients:genetical background of microalbuminuria in obesity. Nefrologia. 2017;37(4):381-388.
15. Pak V. M., Keenan B. T., Jackson N., Grandner M. A., Maislin G. [et al.]. Adhesion molecule increases in sleep apnea: beneficial effect of positive airway pressure and moderation by obesity. Int. J. Obes. (Lond). 2015;39(3):472-479. https://doi.org/10.1038/ijo.2014.123
16. Komshilova K. A. Abdominal obesity and non-alcoholic fatty liver disease: clinical, laboratory and morphological comparisons : dissertation thesis of the candidate of medical sciences. Moscow, 2015. (In Russ.).
17. de Souza I. C., Rosa D. D., Ettrich B., Cibeira G. H., Giacomazzi J. [et al.]. Association of adipokines and adhesion molecules with indicators of obesity in women undergoing mammography screening.Nutr. Metab. (Lond).2012;9(1):97. https://doi.org/10.1186/1743-7075-9-97
18. Thakur M. L., Sharma S., Kumar A., Bhatt S. P., Luthra K. [et al.]. Nonalcoholic fatty liver disease is associated with subclinical atherosclerosis independent of obesity and metabolic syndrome in Asian Indians. Atherosclerosis.
2012;223(2):507-511. https://doi.org/10.1016/j.atherosclerosis.2012.06.005
19. Paltsev M. A., Kvetnoy I. M., Ilnitski A. N., Prashchayeu K. I., Kvetnaia T. V. [et al.]. The obesity: the molecular mechanisms and the optimization of target therapy. Moleculyarnaya meditcina. – Molecular medicine. 2013;2:3-12. (In Russ.).
20. Tang L., Peng H., Xu T., Wang A., Wang G. [et al.]. Association of biomarkers of inflammation with dyslipidemia and its components among Mongolians in China. PLoS ONE. 2014;9(2):e89023. https://doi.org/10.1371/journal.pone.0089023
21. Al-Jiffri O. H., Al-Sharif F. M., Al-Jiffri E. H., Al-Jiffri E. H., Uversky V. N. Intrinsic disorder in biomarkers of insulin resistance, hypoadiponectinemia, and endothelial dysfunction among the type 2 diabetic patients. Intrinsically Disord Proteins. 2016;4(1):e1171278. https://doi.org/10.1080/21690707.2016.1171278
22. Kulkarni H., Mamtani M., Peralta J., Almeida M., Dyer T. D. [et al.]. Soluble forms of intercellular and vascular cell adhesion molecules independently predict progression to type 2 diabetes in Mexican American families. PLoS ONE. 2016;11(3):e0151177. https://doi.org/10.1371/journal.pone.0151177
23. Polovina M. M., Potpara T. S. Endothelial dysfunction in metabolic and vascular disorders. Postgrad. Med. 2014;126(2):38-53. https://doi.org/10.3810/pgm.2014.03.2739
24. Hocaoglu-Emre F. S., Saribal D., Yenmis G., Guvenen G. Vascular cell adhesion molecule 1, intercellular adhesion molecule 1, and cluster of differentiation 146 levels in patients with type 2 diabetes with complications. Endocrinol. Metab. (Seoul). 2017;2(1):99-105. https://doi.org/10.3803/EnM.2017.32.1.99
25. Ruszkowska-Ciastek B., Sokup A., Wernik T., Ruprecht Z., Góralczyk B. [et al.]. Effect of uncontrolled hyperglycemia on levels of adhesion molecules in patients with diabetes mellitus type 2. J. Zhejiang Univ. Sci. B. 2015;16:355-361. https://doi.org/10.1631/jzus.B1400218
26. Chapman M. J., Ginsberg H. N., Amarenco P., Andreotti F., Borén J. [et al.]. Triglyceride-rich lipoproteins and highdensity lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur. Heart J. 2011;32:1345-1361. https://doi.org/10.1093/eurheartj/ehr112
27. Kunutsor S. K., Bakker S. J. L., Dullaart R. P. F. Soluble vascular cell adhesion molecules may be protective offuture cardiovascular disease risk: findings from the PREVEND prospective cohort study. J. Atheroscler. Thromb. 2017;24:804-818. https://doi.org/10.5551/jat.38836

Keywords: non-alcoholic fatty liver disease, metabolic syndrome, adhesion molecules

Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy